Table 1.
Clinical characteristics of 138 SCLC patients.
| Variables | Total | Training group | Validated group | p-value |
|---|---|---|---|---|
| Number | 138 | 108 | 30 | |
| Age, mean±SD, years | 64.8±10.2 | 65.3±10.1 | 63.0±10.7 | 0.280 |
| Male, n (%) | 124 (89.9) | 97 (89.8) | 27 (90) | 1.000 |
| Tumor invasion depth, n (%) | 0.172 | |||
| T1 | 8 (5.8) | 6 (5.5) | 2 (6.7) | |
| T2 | 22 (15.9) | 14 (13.0) | 8 (26.7) | |
| T3 | 35 (25.4) | 31 (28.7) | 4 (13.3) | |
| T4 | 73 (52.9) | 57 (52.8) | 16 (53.3) | |
| Lymph node metastasis, n (%) | 0.676 | |||
| N0 | 8 (5.8) | 5 (4.6) | 3 (10.0) | |
| N1 | 27 (19.5) | 21 (19.4) | 6 (20.0) | |
| N2 | 59 (42.8) | 48 (44.5) | 11 (36.7) | |
| N3 | 44 (31.9) | 34 (31.5) | 10 (33.3) | |
| Distant metastasis, n (%) | 87 (63.0) | 68 (63.0) | 19 (63.3) | 0.970 |
| TNM stage, III/IV, n (%) | 124 (89.9) | 98 (90.7) | 26 (86.7) | 0.755 |
| CTC, mean±SD, n | 13.1±15.9 | 12.5±15.5 | 15.3±17.4 | 0.387 |
| NSE, >25ng/ml, n (%) | 100 (72.5) | 84 (77.8) | 20 (66.7) | 0.212 |
| Cyfra21-1, >3.3ng/ml, n (%) | 94 (68.1) | 70 (64.8) | 24 (80.0) | 0.114 |
| CEA, ≥5ug/L, n (%) | 63 (45.7) | 51 (47.2) | 12 (40.0) | 0.482 |
| SCC, ≥2.5ng/ml, n (%) | 10 (7.2) | 7 (6.5) | 3 (10.0) | 0.795 |
| Treatment mode, n (%) | 0.169 | |||
| chemotherapy | 61 (44.2) | 52 (48.1) | 9 (30.0) | |
| chemotherapy + radiation | 4 (2.9) | 2 (1.9) | 2 (6.7) | |
| surgery | 5 (3.6) | 3 (2.8) | 2 (6.7) | |
| none treatment | 68 (49.3) | 51 (47.2) | 17 (56.6) | |
Abbreviations: SD, standard deviation; NSE, neuron-specific enolase; Cyfra21-1, cytokeratin 19 fragment; CEA, Carcinoembryonic antigen; SCC, squamous cell carcinoma associated antigen; CTC, circulating tumor cells.